https://orcid.org/0000-0002-2889-7265
References
- GBD 2019 cause and risk summaries. Chronic obstructive pulmonary disease - level 3 cause. Available from: https://www.healthdata.org/results/gbd_summaries/2019/chronic-obstructive-pulmonary-disease-level-3-cause. Accessed December 15, 2021.
- GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 [published correction appears in Lancet. 2020 Nov 14;396(10262):1562]. Lancet. 2020;396(10258):1204–1222. doi:10.1016/S0140-6736(20)30925-9
- Kocabas A, Hancioglu A, Turkyilmaz S, et al. Prevalence of COPD in Adana, Turkey (BOLD-Turkey Study). Proc Am Thorac Soc. 2006;3(Suppl):A543.
- Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G, Mutlu LC, Pehlivan E. Prevalence of COPD: first epidemiological study of a large region in Turkey. Eur J Intern Med. 2008;19(7):499–504. doi:10.1016/j.ejim.2007.06.028
- Arslan Z, Ilgazlı A, Etiler N, Hamzaoğlu O. Prevalence of chronic obstructive pulmonary disease in Kocaeli: an industrialised city in Turkey. Balkan Med J. 2013;30(4):387–393. doi:10.5152/balkanmedj.2013.8042
- Örnek T, Tor M, Kıran S, Atalay F. Prevalence of chronic obstructive pulmonary disease in Zonguldak province of Turkey. Tuberk Toraks. 2015;63(3):170–177. doi:10.5578/tt.9582
- Türkiye İstatistik Kurumu (TÜİK), Ölüm ve Ölüm Nedeni İstatistikleri 2019, Turkish [Turkish Statistical Institute (TUIK), Death and Cause of Death Statistics 2019, Turkish]. Available from: https://data.tuik.gov.tr/Bulten/Index?p=Olum-ve-Olum-Nedeni-Istatistikleri-2019-33710. Accessed December 15, 2021.
- Başara BB, Çağlar İS, Aygün A, et al. Sağlık Bilgi Sistemleri Genel Müdürlüğü, Sağlık Bakanlığı, Ankara, 2019, Turkish [General Directorate of Health Information Systems, Ministry of Health, Ankara, 2019, Turkish]. Available from: https://sbsgm.saglik.gov.tr/Eklenti/40564/0/saglik-istatistikleri-yilligi-2019pdf.pdfistatistikleri-yilligi-2019pdf. Accessed December 15, 2021.
- Global initiative for chronic obstructive lung disease. Available from: https://goldcopd.org/. Accessed December 15, 2021.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2019 report. Available from:https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf. Accessed December 15, 2021.
- Gunen H, Yilmaz M, Aktas O, et al. Categorization of COPD patients in Turkey via GOLD 2013 strategy document: ALPHABET study. Int J Chron Obstruct Pulmon Dis. 2015;10:2485–2494. doi:10.2147/COPD.S87464
- Tsiligianni I, Kampouraki M, Ierodiakonou D, Poulonirakis I, Papadokostakis P. COPD patients’ characteristics, usual care, and adherence to guidelines: the Greek UNLOCK study. Int J Chron Obstruct Pulmon Dis. 2019;14:547–556. doi:10.2147/COPD.S185362
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2022 report. Available from: https://goldcopd.org/2022-gold-reports-2. Accessed December 15, 2021.
- Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa1713901
- Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48. doi:10.1056/NEJMoa1916046
- Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, Phase 3 randomised controlled trial [published correction appears in Lancet Respir Med. 2018 Oct 4; [published correction appears in Lancet Respir Med. 2019 Feb;7(2):e9]. Lancet Respir Med. 2018;6(10):747–758. doi:10.1016/S2213-2600(18)30327-8
- Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–973. doi:10.1016/S0140-6736(16)31354-X
- Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial [published correction appears in Lancet. 2018 Feb 26]. Lancet. 2018;391(10125):1076–1084. doi:10.1016/S0140-6736(18)30206-X
- Foo J, Landis SH, Maskell J, et al. Continuing to confront COPD international patient survey: economic impact of COPD in 12 countries. PLoS One. 2016;11(4):e0152618. doi:10.1371/journal.pone.0152618
- Patel JG, Coutinho AD, Lunacsek OE, Dalal AA. COPD affects worker productivity and health care costs. Int J Chron Obstruct Pulmon Dis. 2018;13:2301–2311. doi:10.2147/COPD.S163795
- Souliotis K, Kousoulakou H, Hillas G, Tzanakis N, Toumbis M, Vassilakopoulos T. The direct and indirect costs of managing chronic obstructive pulmonary disease in Greece. Int J Chron Obstruct Pulmon Dis. 2017;12:1395–1400. doi:10.2147/COPD.S132825
- Wacker ME, Jörres RA, Schulz H, et al. Direct and indirect costs of COPD and its comorbidities: results from the German COSYCONET study. Respir Med. 2016;111:39–46. doi:10.1016/j.rmed.2015.12.001
- Rehman AU, Hassali MAA, Muhammad SA, Harun SN, Shah S, Abbas S. The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature. Eur J Health Econ. 2020;21(2):181–194. doi:10.1007/s10198-019-01119-1
- Gutiérrez Villegas C, Paz-Zulueta M, Herrero-Montes M, Parás-Bravo P, Madrazo Pérez M. Cost analysis of chronic obstructive pulmonary disease (COPD): a systematic review. Health Econ Rev. 2021;11(1):31. doi:10.1186/s13561-021-00329-9